On August 28, 2024, the Russian Federation's Ministry of Health Commission met to finalize lists of medicinal products for human use, as well as the minimum range required for healthcare provision. During the meeting, members unanimously agreed to include Atazor-R (atazanavir 300 mg + ritonavir 100 mg), a drug used to treat HIV infection, on the List of Vital and Essential Drugs. The drug's price is set at 1,245 rubles (excluding VAT).

This decision will result in an update of Russian Government Directive No. 2406-р dated October 12, 2019, entitled “On Approval of the List of Vital and Essential Drugs, as well as Lists of Medicinal Products for Human Use and the Minimum Range of Drugs Required for Healthcare Provision.” As a result, Atazor-R will be eligible for federally funded procurement, greatly increasing patient access to effective therapy.

Atazor-R is a fixed-dose combination of protease inhibitors: atazanavir (300 mg), boosted with ritonavir (100 mg). According to estimates from healthcare regulators and leading HIV specialists, the drug could benefit 30,000 patients.

The approval by the Commission came after extensive and coordinated efforts by a cross-functional team that prepared materials for the meeting of the Russian Federation's Ministry of Health.